title: [Anti-Helicobacter pylori antibodies in cases of stomach polyps].
abstract: The goal of the study was to study the content of anti-Helicobacter pylori antibodies (at-HP), their diagnostic and prognostic significance for stomach polyps.
  
  
  METHODS
  The content of anti-Helicobacter antibodies (IgG-HP; IgA-HP; IgM + IgG + IgA-CagA-HP) was determined in the blood serum by way of immune-enzyme analysis of 46 patients with stomach polyps. Such test systems as EcoLab (Elektrostal) and Vector-Best (Novosibirsk) were used.
  
  
  RESULTS
  Stomach polyps are accompanied by a regular increase of at-HP--serologic markers of helicobacteriosis content in the blood serum. The most significant increase in terms of percentage and absolute values is the IgG-HP concentration increase (88%, average titre 1: 1060, in the control group--1: 110) and summary (IgM + IgG + IgA) antibodies to CagA-HP (86%, average titre 1 : 180, in the control group 1 : 10), while the IgA-HP level is increased in 46%, average titre 1 : 660, in the control group 1 : 120). The IgG-HP content increase reflects the inflammatory process intensity, IgA-HP--atrophic process intensity, (IgM + IgG + IgA)-CagA-HP--1 intensity of proliferative processes of stomach polyps.
  
  
  CONCLUSIONS
  The at-HP content increase is a diagnostic criterion for helicobacteriosis and reflects the intensity of infectious, inflammatory, atrophic and proliferative processes in cases of stomach polyps. A multiple long-lasting increase of the at-HP concentration may be one of the indications for administering an antihelicobacter stomach polyp therapy including administration before polypectomy.
authors.forename: L B
authors.initials: LB
authors.lastname: Lazebnik
authors.forename: T M
authors.initials: TM
authors.lastname: Tsaregorodtseva
authors.forename: T I
authors.initials: TI
authors.lastname: Serova
authors.forename: M V
authors.initials: MV
authors.lastname: Klishina
authors.forename: E A
authors.initials: EA
authors.lastname: Dubtsova
authors.forename: A V
authors.initials: AV
authors.lastname: Gubina
authors.forename: D A
authors.initials: DA
authors.lastname: Ul'ianov
mesh_terms: D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis*; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011127:Polyps / Q000175:diagnosis* / Q000382:microbiology; D011379:Prognosis; D013272:Stomach Diseases / Q000175:diagnosis* / Q000382:microbiology
chemical_list: D000907:Antibodies, Bacterial; D007136:Immunoglobulins